secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001628280-24-029108
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology shareholders approve increase in shares under 2021 equity plan to 8.15M
--------------------------------------------------------------------------------

- All seven director nominees elected: For votes ranged 15.2M–15.5M; no director received >601K abstentions.
- Ratification of BDO USA as auditor for FY2024 approved: 27.1M For, 0.26M Against, 0.33M Abstain.
- Amendment to 2021 Equity Incentive Plan increasing authorized shares to 8,150,000 approved: 13.1M For, 2.4M Against, 0.35M Abstain.
- Advisory vote on executive compensation passed: 13.3M For, 2.1M Against, 0.41M Abstain.
- All proposals passed; broker non-votes noted for director election, equity plan, and say-on-pay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024029108/0001628280-24-029108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024029108/crdf-20240620.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-029108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer